Pharma-Bro Learns The Cost Of His Douchbaggery, Company Loses $14.6 Million Last Quarter


More bad news for pharma-bro Martin Shkreli. His company lost almost $15 million last quarter as a result of his crappy attitude and behavior.

Shkreli’s company, Turing Pharmaceuticals, just reported a net loss of $14.6 million in their third-quarter of this year. The quarter stretched from July through September, during which Shkreli became Public Enemy #1 when he raised the price of Daraprim, a drug used by some HIV patients, by more than 5,000 percent overnight, going from $13.50 to $750 per tablet.

Related: Five Fun Facts About Martin Shkreli And The Daraprim Drama

At the time, 32-year-old Shkreli responded to criticism over the price increase not by apologizing but rather by launching into an unapologetic Twitter rampage, where he seemed to delight in being labeled a “super villain.” After being called a “spoiled brat” by Donald Trump and having his campaign donation rejected by Bernie Sanders, Shkreli eventually told NBC News he would be lowering the price of Daraprim. That was in September, however, and he’s yet to actually make good on the promise.

We’re sure Shkreli pooped his pants over this latest news, but he’s still trying to display an I-don’t-give-a-shit attitude on Twitter because, well, that’s what he does. Yesterday, he tweeted:

We’ve heard disturbing rumors that karma’s a bitch.

Related: Who Is The Biggest Douche Of The Year? You Decide!

Don't forget to share:

Help make sure LGBTQ+ stories are being told...

We can't rely on mainstream media to tell our stories. That's why we don't lock Queerty articles behind a paywall. Will you support our mission with a contribution today?

Cancel anytime · Proudly LGBTQ+ owned and operated